LGT Capital Partners’ China Insights Tour 2026

We are pleased to invite you to LGT Capital Partners’ China Insights Tour 2026. This event will be held across Beijing and Shanghai, from 15 to 18 June 2026. While the event was initially scheduled for May, we have postponed it in light of the global situation.


At LGT Capital Partners, we have more than 20 years of experience investing in China and have built local presence in Hong Kong since 2003 and in Beijing since 2012. We look forward to sharing our market insights and bringing you closer to the market through a week-long program held in multiple cities across the country.


The week is designed to give you first-hand perspective into the Chinese private equity ecosystem, by meeting with top performing GPs and visiting portfolio companies that are already global leaders or emerging sector innovators.


The program will start on Monday morning 15 June 2026 in Beijing and will end on Thursday afternoon in Shanghai. We recommend participants to book their return flight directly from Shanghai for the evening of 18 June 2026 or on 19 June 2026. LGT Capital Partners will organize and cover accommodation and local transfers for your convenience.


‎‎If you have any questions, please do not hesitate to contact us.


We look forward to welcoming you to an insightful and engaging week.

Kind regards,
Wael El Burji

Agenda

Arrival dinner

*subject to change

Registration

GP & company short descriptions

Linear Capital

Founded in 2014 by the first Chinese engineer at Facebook (Meta), Linear Capital is focused on tech-oriented early-stage investments in China. Known as the early backer of several prominent venture start-ups such as Horizon Robotics (HKEX: 9660), EHang (NASDAQ: EH), Agile Robots, Manycore Tech (Kujiale), D-Robotics, etc., the GP currently manages USD 2 billion in assets under management.

Agile Robots (Linear Capital portfolio company)

Agile Robots SE is a deep-tech company that combines advanced robotics and artificial intelligence to deliver next-generation automation solutions for industry and services. Founded in 2018 by former German Aerospace Center (DLR) researchers Dr. Zhaopeng Chen and Peter Meusel, the company focuses on making production environments smarter, more flexible and more efficient. Its portfolio spans industrial robot arms, mobile robotics, dexterous robotic hands and the AgileCore software and control platform, recently expanded by the humanoid robot Agile ONE for “Physical AI” in factories.

Monolith

Founded in 2021 by ex-Hongshan (fka Sequoia China) star performer, Xi Cao, Monolith is a new generation venture manager focusing on AI and tech-enabled early-stage opportunities in China. Despite it’s young age, Monolith has successfully raised two USD funds, both of which have been oversubscribed and supported by prominent institutions. It has also invested in many young but prominent start-ups such as Moonshot (known for its large language model Kimi) among others.

Pony.ai

Pony.ai (NASDAQ:PONY, HKEX:2026) is a global leader in autonomous driving technology, founded in 2016 by a core team from Baidu. The company specializes in L4 autonomous driving solutions with core businesses covering robotaxi, robotruck and technology licensing.

Xiaomi Auto

Xiaomi Corp (HKEX: 1810) is a global technology leader founded in 2010. It’s core businesses include smartphones, AIoT solutions, and, more recently, smart electric vehicles. Xiaomi Auto was launched in 2021. By February 2026, cumulative deliveries surpassed 600’000 units, driven by the successful debut Su7 model in 2024.

Black Ant Capital (Aka BA Capital)

Founded in 2016 and having raised its first USD fund in 2020, BA Capital (Black Ant Capital) is one of China’s most highly regarded growth-stage consumer investment specialists. To date, the GP has raised three RMB funds and two USD funds. The firm has been a key investor in several well-known companies, including Pop Mart (creator of the popular Labubu doll, listed on HKEX: 9992) and Laopu Gold (a premium Chinese-style gold jewellery brand, listed on HKEX: 6181), among others.

Boyu Capital

Founded in 2011, Boyu is widely as one of China’s leading private equity firms. Since inception it has executed numerous landmark transactions, including Wuxi Pharma Tech (China’s largest CRO/CDMO company, where Boyu led the consortium of its public-to-private deal), CATL (the world’s largest lithium battery producer), and Starbucks China (acquiring a controlling stake in the China business from the U.S. parent). The firm has also made significant minority investments inmany of China’s most prominent sector leaders such as Alibaba, Didi, Meituan and Kuaishou.

Qiming

Founded in 2006, Qiming is a top-tier venture capital firm focused on the Technology & Consumer and Healthcare sectors in China. Since inception, the firm has raised over USD 9 billion across eight USD funds and seven RMB funds and is widely recognized for its consistent performance across cycles, deep technology expertise and influential portfolio ecosystem. Representative investments include Xiaomi (HKEX:1810), Bilibili (NASDAQ:BILI, HKEX:9626), UBTech (HKEX:9880), APT Medical (HKEX:688617), Tigermed (SZSE:300347, HKEX:3347), Zai Lab (NASDAQ:ZLAB, HKEX:9688), CanSino Biologics (SEHK:6185, SHSE:688185), Sanyou (SHSE:688085) and Structure Therapeutics (Nasdaq:GPCR). Of the approximately 540 companies backed by Qiming, more than 80 have have reached unicorn status and over 200 have achieved exits through IPOs, M&A or other liquidity events.

Centurium Capital

Founded in 2018 by the former head of Warburg Pincus China, Centurium Capital focuses on buyout and late-stage growth investments in China. Since its inception, the GP has raised two USD-denominated funds. Its portfolio includes investments such as Luckin Coffee (OTC: LKNCY), Taibang Biologic Group, Ane Logistics (HKEX: 9956), among others.

Luckin Coffee (Centurium portfolio company)

Founded in 2017, Luckin Coffee Inc. has grown into China’s largest and fastest-growing coffee brand and retail chain, operating more than 29’000 stores nationwide, including 18’882 self-operated and 10’332 partnership locations.

Insilico Medicine

Insilico Medicine (HKEX:3696) is a pioneering global biotech company founded in 2015, specializing in the use of generative AI to accelerate drug discovery and development. Its business model combines, out-licensing of its AI-driven software platform with the development of an in-house therapeutic pipeline. As of December 2025, the company has established partnerships with 13 of the world’s top 20 pharmaceutical companies and has three major out-licensed assets with a total potential contract value of USD 2 billion.

CAIT (Contemporary Amperex Intelligence Technology)

Incubated by CATL, the world’s largest lithium battery producer, CAIT is a global leader in integrated intelligent electric-chassis solutions featuring advanced Cell-to-Chassis (CTC) technology. Although still a young, pre-revenue business, it represent a core strategic initiative within the CATL ecosystem and has the potential to reshape the EV industry by enabling the next generation of emerging EV brands particularly in the global markets.

Transfer and Logistics

Arrival in Beijing & Accommodation

The program will commence on Monday morning, 15 June 2026, in Beijing and conclude on Thursday afternoon in Shanghai.

LGT Capital Partners will arrange and cover accommodation as well as local transfers throughout the week for your convenience.

To ensure a timely start of the program, participants are kindly requested to plan their arrival in Beijing for the evening of 14 June 2026 or no later than the early morning of 15 June 2026.

Flight from Beijing to Shanghai

Our team will arrange all transfers during the Insights Tour, including the domestic flight from Beijing to Shanghai.

Departure from Shanghai

We recommend participants to book their return flight directly from Shanghai for the evening of 18 June 2026 or on 19 June 2026.

Contact

If you have any questions, please contact us.